Compounds, such as colchicines [20], beraprost sodium [27], and mycophenolate mofetil [28], have been demonstrated to ameliorate inflammatory cell infiltration in diabetic nephropathy by inhibiting MCP-1 expression. Here, CCL2 is linked to diabetic kidney disease.